Narrative Persuasion 2

Last registered on June 23, 2023

Pre-Trial

Trial Information

General Information

Title
Narrative Persuasion 2
RCT ID
AEARCTR-0011565
Initial registration date
June 12, 2023

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
June 23, 2023, 4:21 PM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

Region

Primary Investigator

Affiliation
WZB

Other Primary Investigator(s)

PI Affiliation
WZB

Additional Trial Information

Status
In development
Start date
2023-06-13
End date
2024-01-31
Secondary IDs
Prior work
This trial does not extend or rely on any prior RCTs.
Abstract
This pre-registration describes two sets of additional treatments that we will conduct to complement those that have already been described in the working paper (https://www.cesifo.org/DocDL/cesifo1_wp10206.pdf).
External Link(s)

Registration Citation

Citation
Barron, Kai and Tilman Fries. 2023. "Narrative Persuasion 2." AEA RCT Registry. June 23. https://doi.org/10.1257/rct.11565-1.0
Experimental Details

Interventions

Intervention(s)
Please see the attached pdf for details.
Intervention (Hidden)
Please see the attached pdf for details.
Intervention Start Date
2023-06-13
Intervention End Date
2023-06-30

Primary Outcomes

Primary Outcomes (end points)
Advisor's messages and investor's beliefs (Please see the attached pdf for details.)
Primary Outcomes (explanation)
Please see the attached pdf for details.

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
We exogenously vary contextual factors that may play a role in influencing persuasion using narratives.
Experimental Design Details
Please refer to the attached pdf for details.
Randomization Method
The randomization is implemented by the computer software, oTree, that was used to programme this experiment.
Randomization Unit
We have multiple layers or randomization. These are described in detail in our attached pdf.

Our main between-individual randomization will be done at the individual level. Within each pair of treatments, individuals have an equal (50%) chance of being randomized into each treatment condition.

In addition, we add exogenous variation in the individual rounds that an individual completes. Much of this is similar to the randomization described in detail in our working paper https://www.cesifo.org/DocDL/cesifo1_wp10206.pdf. The attached pdf in this pre-registration provides details.
Was the treatment clustered?
Yes

Experiment Characteristics

Sample size: planned number of clusters
This is described in the analysis section of our attached pdf.
Sample size: planned number of observations
720
Sample size (or number of clusters) by treatment arms
Each treatment contains 180 individuals. The details are provided in the attached pdf.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
This is provided in the attached pdf.
Supporting Documents and Materials

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information
IRB

Institutional Review Boards (IRBs)

IRB Name
WZB Research Ethics Committee
IRB Approval Date
2021-09-10
IRB Approval Number
2021/3/122

Post-Trial

Post Trial Information

Study Withdrawal

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Intervention

Is the intervention completed?
No
Data Collection Complete
Data Publication

Data Publication

Is public data available?
No

Program Files

Program Files
Reports, Papers & Other Materials

Relevant Paper(s)

Reports & Other Materials